Skip to content

Diuretic Versus Placebo in Pulmonary Embolism

Diuretic Versus Placebo in Pulmonary Embolism With Right Ventricular Enlargement: a Double-blind Randomized Controlled Study

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02268903
Acronym
DiPER
Enrollment
270
Registered
2014-10-20
Start date
2015-04-13
Completion date
2018-05-31
Last updated
2017-10-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Embolism With Right Ventricle Enlargement

Keywords

Pulmonary Embolism, Right Ventricle failure, Diuretics

Brief summary

Pulmonary Embolism (PE) is a frequent and severe disease with an annual incidence of about 75000 cases in France and a short-term mortality rate of about 10%. Death is usually related to an acute right ventricular (RV) failure due to the increase in right ventricular afterload. Treatment of PE with RV failure consists in fluid expansion and thrombolysis in case of shock. However several studies suggest that fluid expansion may worsen acute RV failure by increasing RV dilatation and ischemia and left ventricular compression by RV dilatation. Thus, current guidelines regarding PE treatment remain unclear about the use of fluid expansion. In a preliminary study published by our group, we showed that diuretic treatment in the setting of PE with RV dilatation is safe and is associated with an increase in urine output, a decrease in heart rate and an increase in SpO2 in normotensive patients with oliguria. This may be related to the decrease of ventricular interdependence and enhancement of both LV and RV function. The main objective of the study is to evaluate the 24-hours clinical benefit of furosemide in patients referred for acute PE with RV dilatation compared to placebo. The combination of urine output and sPESI clinical parameters reflects hemodynamic status. It is relevant as it indicates the disappearance of pre-shock symptoms and is therefore associated with a lower event risk. Thus, it allows early discharge of the patients from the intensive care unit.

Interventions

DRUGDiuretics : Furosemide

Furosemide 80mg in one single direct intra venous injection

DRUGPlacebo

Placebo in one single direct intra venous injection

Sponsors

Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Patients aged 18 years and over with 1. Symptomatic acute pulmonary embolism with first clinical symptoms within 15 days, and objectively confirmed by CT scan 2. RV dysfunction (≥1 criterion) confirmed by elevated BNP value or echocardiography or spiral computed tomography of the chest: * Echocardiography o Right/Left ventricular end diastolic diameter \> 1(apical or subcostal 4-chamber view) * Computed tomography o Right/Left short-axis diameter ratio\>0.9 (transverse plane) * Positive Nt-proBNP (\>600) or BNP\>200 pg/mL 3. One abnormal following PESI criteria * Heart Rate\>110/min * Systolic blood pressure\<100mmHg * Arterial oxyhemoglobin level\<90% on room air or after 5 minutes of oxygen withdrawal.

Exclusion criteria

* Cardiogenic shock requiring thrombolysis * Previous significant left ventricular insufficiency (LVEF\<45%) * Systolic blood pressure\<90mmHg at admission * Age ≤ 18 years * Pregnancy * No health insurance * Patients deprived of liberty or under legal protection * Creatinin clearance \<30mL/min/m² * hypersensibility to furosemide or its excipients * functional renal insufficiency * Hepatic encephalopathy * Urinary tracks obstruction * Hypovolemia or dehydration. * Sever hypokalemia (K+ \< 3mmol/L) * Severe hyponatremia (Na+ \< 125mmol/L) * Ongoing hepatitis and hepatic insufficiency severe in patients with renal insufficiency or dialysis

Design outcomes

Primary

MeasureTime frameDescription
Primary end point will be a combined clinical criterion, to reach the primary endpoint, patients have to meet all the following criteria: - Urine output> 0.5ml/kg/h - Normalization of clinical parameters of simplified PESI score24 hoursNormalization of clinical parameters of simplified PESI score : * Heart Rate\<110/min * Systolic blood pressure≥100mmHg * Arterial oxyhemoglobin level\>90% on room air or after 5 minutes of oxygen withdrawal.

Secondary

MeasureTime frameDescription
patients have to meet all the four following criteria: - Urine output> 0.5ml/kg/h over 24 hours - Normalization of clinical parameters of simplified PESI score - Urine output48 hoursNormalization of clinical parameters of simplified PESI score : * Heart Rate\<110/min * Systolic blood pressure≥100mmHg * Arterial oxyhemoglobin level\>90% on room air or after 5 minutes of oxygen withdrawal.
- Composite criteria including death, need for catecholamine, cardiac arrest and mechanical ventilation during hospitalization and at 1 month from inclusion - NYHA scoreIn hospital and 1 month
o RV/LV ratio and decrease from baseline o Systolic pulmonary pressure and decrease from baseline o Tricuspid annular plane systolic expansion (TAPSE) at o Tricuspid annular plane systolic expansion (TAPSE) variation from baseline24 hours abd 1 monthRV/LV ratio (diameters and surfaces)
- NT-proBNP or BNP decrease at 24hours - Creatinin and liver enzymes variations at 24hours24 hours

Countries

France

Contacts

Primary ContactJean-Luc DUBOIS-RANDE, PU-PH
jean-luc.duboisrande@hmn.aphp.fr(0)1 49 81 36 02
Backup ContactRomain GALLET, CCA
romain.gallet@yahoo.fr(0)1 49 81 36 02

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 4, 2026